Navigation Links
Trial Drug Shows Preliminary Promise Against Ovarian Cancer
Date:8/22/2011

SUNDAY, Aug. 21 (HealthDay News) -- An experimental drug that's shown promise against ovarian cancer caused by mutations in the BRCA1 or BRCA2 genes may also be effective against ovarian cancer not caused by those gene mutations, according to a new study.

Olaparib blocks the activity of a protein called poly ADP ribose polymerase (PARP). Both PARP and BRCA proteins are involved in DNA repair. Clinical trials of olaparib in patients with BRCA 1 and 2 mutations have yielded promising results, the study authors noted.

In the new study, Canadian researchers say they're the first to show that olaparib reduces tumor size in patients with non-hereditary (sporadic) ovarian cancer, which is much more common than BRCA-mutated ovarian cancers.

The phase 2 trial included 65 ovarian cancer patients who received 400 milligrams of olaparib twice daily for four weeks. Measurable tumor shrinkage was seen in 41 percent of patients with BRCA mutations and in 24 percent of those without BRCA mutations, the researchers said.

The study was published online Aug. 21 in The Lancet Oncology.

Side effects were described as mild and included fatigue, nausea, vomiting and decreased appetite, study lead author Karen Gelmon, of the B.C. Cancer Agency in Vancouver, and colleagues said in a news release from the journal.

"This finding not only suggests new therapeutic possibilities for women with this aggressive type of ovarian cancer, but also importantly confirms the hypothesis that subpopulations of patients with common sporadic tumors can be targeted effectively with PARP inhibitor therapy," Dr. Melinda Telli, of Stanford University School of Medicine, wrote in an accompanying editorial.

Another expert agreed. Dr. Stephanie V. Blank is an assistant professor in clinical gynecologic oncology at NYU School of Medicine. She said: "It is extremely exciting that an agent as promising as olaparib can be effective in a broad
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Superdrug Against Range of Viruses Shows Promise in Animal Trials
2. New TB vaccine enters proof-of-concept trial in people living with HIV
3. ESC announces review of Atrial Fibrillation Guidelines
4. University Hospitals Case Medical Center to begin clinical trial on experimental anti-TB drug
5. New clinical trial to examine medication to treat social withdrawal in Fragile X and autism
6. VOICE study will continue as it considers what action to take after results of 2 trials
7. Covidien supports NOSCAR US multicenter human trial
8. Amrubicin improved response rate and progression-free survival vs. topotecan in Phase III trial
9. Patient Disparities Seen in Lung Cancer Drug Trials
10. Women, elderly, minorities poorly represented in lung cancer drug trial data submitted to US FDA
11. Massage eases low back pain in randomized controlled trial
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Trial Drug Shows Preliminary Promise Against Ovarian Cancer
(Date:8/27/2014)... Recently, Skmen.com, a renowned garment manufacturer and retailer, has ... . The company has rich experience in making fashionable ... stock and ready to ship: celebrity bodycon dresses, mini ... and so forth. All of them are available in ... proud to announce the new collection of celebrity bodycon ...
(Date:8/27/2014)... August 27, 2014 Taking its popular obstacle ... Steele Creek YMCA will host its largest crowd at ... Saturday, September 13 at YMCA Camp Thunderbird . ... divisions: adult, youth and teams. Within each division, runners ... their physical limit - for a worthy cause. All ...
(Date:8/27/2014)... 2014 Today, Zane Benefits, the #1 ... tips for administering a premium reimbursement plan. , ... effect, compliance is top of mind for employers, health ... health insurance and premium reimbursement, there are important compliance ... 35 minute webinar, Zane Benefits President, Rick Lindquist, will ...
(Date:8/27/2014)... Skirt Sports , the innovative women’s running apparel ... Kathrine Switzer, most noted for her brave running of the ... of women’s running clothes that unites the history of women’s ... Movement. , “It is such an honor to ... “Kathrine is the original Skirt – she stood strong, pushing ...
(Date:8/27/2014)... the use of hormone therapy has spawned a prevalent ... silence with hot flashes, according to a study by ... , In the study published in the Aug. 27 ... team found that moderate to severe hot flashes ... in most women. Women with VMS experience more than ...
Breaking Medicine News(10 mins):Health News:Skmen.com Unveils Its New Celebrity Bodycon Dresses for Its Loyal Customers 2Health News:C2 Survival Racers Go to Extremes to Provide Kids with YMCA Programs 2Health News:Zane Benefits Announces Upcoming Webinar on Compliance 2Health News:Skirt Sports Launches Clothing Line with Legendary Runner Kathrine Switzer 2Health News:The high cost of hot flashes: Millions in lost wages preventable 2
... Upgrades new facility from film to IDC 1600 ... - IDC (Imaging Dynamics Company,Ltd.) (TSX: IDL), the ... radiography (DR), today announced that HealthPartners Medical Group,of ... X-Series DR system.,HealthPartners is a multi-specialty physician group ...
... a range of $395 Million to $405 Million; ... ... up 57.4% over first quarter 2007 - Gross profit of $23.9 million, ... up 135.4% over first quarter 2007, WARSAW, Ind., June 24 Symmetry Medical ...
... Exposure Increased 38% From 2001 - 2007, ... advertising practices by alcohol companies from 2001-2007,finds an ... relatively,few industry- sponsored "responsibility" ads. The new study, ... Youth (CAMY) at Georgetown,University, evaluated advertising trends and ...
... Research,Inc. (ADR), one of the world,s leading scientific institutes ... to announce that it,has achieved legal status as a ... fully-operational for a while now," says,Dr. Catlin, a founder ... all official and we,re thrilled, because others can now ...
... China, TUSTIN, Calif., June 24 AMDL, ... specialty pharmaceuticals,announced today its subsidiary Jade Pharmaceutical, Inc. ... two new formulations of its,popular Goodnak(R) anti-aging skin ... injectable formulation, JPI anticipates offering Goodnak in,capsules and ...
... ultrasound exam of the heel may be able to predict ... to osteoporosis, according to a new multicenter study being published ... Along with certain risk factors, including age or recent fall, ... select women who need further bone density testing, such as ...
Cached Medicine News:Health News:HealthPartners Medical Group in Michigan City purchases IDC digital radiography system 2Health News:HealthPartners Medical Group in Michigan City purchases IDC digital radiography system 3Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 2Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 3Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 4Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 5Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 6Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 7Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 8Health News:Alcohol Advertisements Seen by Youth on TV on the Rise, According to a New Report by the Center on Alcohol Marketing and Youth 2Health News:Alcohol Advertisements Seen by Youth on TV on the Rise, According to a New Report by the Center on Alcohol Marketing and Youth 3Health News:Leading Performance-Enhancing Drug Research Institute Anti-Doping Research (ADR) Establishes Nonprofit Status 2Health News:AMDL's Goodnak(R) Anti-Aging Skin Care Line Soon Available in Capsule & Lotion Form 2Health News:Simple ultrasound exam may predict osteoporosis risk 2
(Date:8/27/2014)... LONDON , Aug. 27, 2014 /PRNewswire/ ... research report: Collaborative R&D Terms ... https://www.reportbuyer.com/product/2276220/Collaborative-RD-Terms--Agreements-in-Pharma-Biotech-and-Diagnostics.html The ... Biotech and Diagnostics report provides comprehensive understanding ... deals and agreements entered into by the ...
(Date:8/27/2014)... , Aug. 27, 2014 /PRNewswire-iReach/ -- In ... to bridge the gap between the electronic medical ... embedded links, readers can experience, first-hand, how seamless ... record. Photo - http://photos.prnewswire.com/prnh/20140827/140443 ... central access to imaging from within the patient ...
(Date:8/27/2014)... 27, 2014 About 8 million Americans have ... buildup of fatty plaque in the arteries, according to ... population and in incidences of diabetes and obesity, the ... Lower Extremity Arterial RevascularizatioN (LEARN) meeting, Oct. 9–11 ... and interested residents and fellows will be able to ...
Breaking Medicine Technology:Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 4Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 5Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 6Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 7Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 8Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 9DICOM Grid Launches Interactive Guide to Demonstrate Image-Enabling the EMR 2LEARN to Treat Peripheral Arterial Disease Patients 2LEARN to Treat Peripheral Arterial Disease Patients 3
... Essence Orthopaedics, Inc., a medical device company focused on ... has introduced their novel, surgeon-designed PONTiS™ Knotless Endotendonous Repair ... Society for Surgery of the Hand (ASSH). ... upper and lower extremity markets, Core Essence Orthopaedics developed ...
... Optimer Pharmaceuticals (NASDAQ: OPTR ) today ... DIFICID™ (fidaxomicin) tablets will be presented at the 2011 ... place September 17-20 in Chicago. DIFICID was approved by ... of 2011 for the treatment of Clostridium difficile ...
Cached Medicine Technology:Core Essence Orthopaedics Unveiled New Flexor Tendon Repair System at ASSH 2011 2Optimer Pharmaceuticals' DIFICID Featured in 11 Presentations at 51st ICAAC 2Optimer Pharmaceuticals' DIFICID Featured in 11 Presentations at 51st ICAAC 3Optimer Pharmaceuticals' DIFICID Featured in 11 Presentations at 51st ICAAC 4Optimer Pharmaceuticals' DIFICID Featured in 11 Presentations at 51st ICAAC 5
... Pulse Oximeter monitors SpO2, pulse ... is designed to provide fast, ... The device rejects spontaneous motion ... operator of excess artifacts and ...
... Radical can operate in two additional ... be removed, creating a fully featured handheld ... also be used to upgrade existing equipment ... additinal hardware or software upgrades to improve ...
Halogen-free immersion oil based on ester oil....
Immersion Oil, 150 cs...
Medicine Products: